NCT00367276View on ClinicalTrials.gov

Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

PHASE3CompletedINTERVENTIONAL

Enrollment

221

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

May 31, 2004

Conditions

Healthy

Interventions

DRUG

Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)

Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.